pubmed.ncbi.nlm.nih.gov

Metformin for endometrial hyperplasia - PubMed

  • ️Fri May 02 2025

Review

. 2024 May 2;5(5):CD012214.

doi: 10.1002/14651858.CD012214.pub3.

Affiliations

Review

Metformin for endometrial hyperplasia

Hunain Shiwani et al. Cochrane Database Syst Rev. 2024.

Abstract

Background: Endometrial cancer is one of the most common gynaecological cancers in the world. Rates of endometrial cancer are rising, in part because of rising obesity rates. Endometrial hyperplasia is a precancerous condition in women that can lead to endometrial cancer if left untreated. Endometrial hyperplasia occurs more commonly than endometrial cancer. Progesterone tablets that are currently used to treat women with endometrial hyperplasia are associated with adverse effects in up to 84% of women. A levonorgestrel intrauterine device may improve compliance, but it is invasive, is not acceptable to all women, and is associated with irregular vaginal bleeding in 82% of cases. Therefore, an alternative treatment for women with endometrial hyperplasia is needed. Metformin, a drug that is often used to treat people with diabetes, has been shown, in some human studies, to reverse endometrial hyperplasia. However, the effectiveness and safety of metformin for treatment of endometrial hyperplasia remain uncertain. This is an update of a review first published in 2017.

Objectives: To determine the effectiveness and safety of metformin in treating women with endometrial hyperplasia.

Search methods: We searched the Cochrane Gynaecology and Fertility Specialised Register, CENTRAL, MEDLINE, PubMed, Embase, Google Scholar, OpenGrey, LILACS, and two trials registers from inception to 5 September 2022. We searched the bibliographies of all relevant studies, and contacted experts in the field for any additional trials.

Selection criteria: We included randomised controlled trials (RCTs) and cross-over trials comparing metformin (used alone or in combination with other medical therapies) versus placebo, no treatment, any conventional medical treatment, or any other active intervention for women with histologically confirmed endometrial hyperplasia of any type.

Data collection and analysis: Two review authors independently assessed studies for eligibility, extracted data from included studies, assessed the risk of bias in the included studies, and assessed the certainty of the evidence for each outcome. We resolved disagreements by discussion or by deferring to a third review author. When study details were missing, review authors contacted the study authors. The primary outcome of this review was regression of endometrial hyperplasia histology (with or without atypia) towards normal histology.

Main results: We included seven RCTs, in which a total of 387 women took part. In the comparison, Metformin plus megestrol versus megestrol alone, we rated the certainty of the evidence as low for the outcome, regression of endometrial hyperplasia. We rated the quality of the evidence as very low for the rest of the outcomes, in all three comparisons. Although there was a low risk of selection bias, there was a high risk of bias in the blinding of personnel and outcome assessment (performance bias and detection bias) in many studies. This update identified four new RCTs and six ongoing RCTs. Metformin versus megestrol We are uncertain whether metformin increases the regression of endometrial hyperplasia towards normal histology over megestrol (odds ratio (OR) 4.89, 95% confidence interval (CI) 1.56 to 15.32; P = 0.006; 2 RCTs, 83 participants; I² = 7%; very low-certainty evidence). This evidence suggests that if the rate of regression with megestrol is 61%, the rate of regression with metformin would be between 71% and 96%. It is unresolved whether metformin results in different rates of abnormal uterine bleeding or hysterectomy compared to megestrol. No study in this comparison reported progression of hyperplasia to endometrial cancer, recurrence of endometrial hyperplasia, health-related quality of life, or adverse effects during treatment. Metformin plus megestrol versus megestrol monotherapy The combination of metformin and megestrol may enhance the regression of endometrial hyperplasia towards normal histology more than megestrol alone (OR 3.27, 95% CI 1.65 to 6.51; P = 0.0007; 4 RCTs, 258 participants; I² = 0%, low-certainty evidence). This suggests that if the rate of regression with megestrol monotherapy is 54%, the rate of regression with the addition of metformin would be between 66% and 84%. In one study, 3/8 (37.5%) of participants who took metformin had nausea that settled without further treatment. It is unresolved whether the combination of metformin and megestrol results in different rates of recurrence of endometrial hyperplasia, progression of endometrial hyperplasia to endometrial cancer, or hysterectomy compared to megestrol monotherapy. No study in this comparison reported abnormal uterine bleeding, or health-related quality of life. Metformin plus levonorgestrel (intrauterine system) versus levonorgestrel (intrauterine system) monotherapy We are uncertain whether there is a difference between groups in the regression of endometrial hyperplasia towards normal histology (OR 0.29, 95% CI 0.01 to 7.56; 1 RCT, 46 participants; very low-certainty evidence). This evidence suggests that if the rate of regression with levonorgestrel monotherapy is 96%, the rate of regression with the addition of metformin would be between 73% and 100%. It is unresolved whether the combination of metformin and levonorgestrel results in different rates of abnormal uterine bleeding, hysterectomy, or the development of adverse effects during treatment compared to levonorgestrel monotherapy. No study in this comparison reported recurrence of endometrial hyperplasia, progression of hyperplasia to endometrial cancer, or health-related quality of life.

Authors' conclusions: Review authors found insufficient evidence to either support or refute the use of metformin, specifically megestrol acetate, given alone or in combination with standard therapy, for the treatment of women with endometrial hyperplasia. Robustly designed and adequately powered randomised controlled trials, yielding long-term outcome data are still needed to address this clinical question.

Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

PubMed Disclaimer

Conflict of interest statement

Declarations at March 2024 are as made for the first published verison of this review in October 2017.

WA is a Professor of Obstetrics and Gynaecology at Mohamed Bin Rashid University of Medicine and Health Sciences in Dubai, United Arab Emirates. He was previously a Clinical Associate Professor and a Consultant Gynaecologist at Queen's Medical Centre, at Nottingham, in the UK. He previously submitted an application to the Nottingham Clinical Trials Unit (in the process of developing a research grant application to the UK NIHR) to conduct a clinical trial comparing metformin with progesterone for treatment of endometrial hyperplasia. A systematic review was suggested to support the trial.

HS, NC and JD have no interests to declare.

Update of

  • Metformin for endometrial hyperplasia.

    Clement NS, Oliver TR, Shiwani H, Sanner JR, Mulvaney CA, Atiomo W. Clement NS, et al. Cochrane Database Syst Rev. 2017 Oct 27;10(10):CD012214. doi: 10.1002/14651858.CD012214.pub2. Cochrane Database Syst Rev. 2017. PMID: 29077194 Free PMC article. Updated. Review.

Similar articles

Cited by

References

References to studies included in this review

Ravi 2021 {published data only}
    1. Ravi RD, Kalra J, Srinivasan R, Bagga R, Jain V, Suri V, et al. A randomized clinical trial of levonorgestrel intrauterine system with or without metformin for treatment of endometrial hyperplasia without atypia in indian women. Asian Pacific Journal of Cancer Prevention : APJCP 2021;22(3):983-9. [DOI: 10.31557/APJCP.2021.22.3.983] - DOI - PMC - PubMed
Sayyah Melli 2018 {published data only}
    1. Sayyah-Melli M, Mostafa-Gharabaghi P, Rahmani V. Comparison of metformin + megestrol acetate and megestrol alone on endometrial abnormal histology. International Journal of Obstetrics and Gynecology 2018;143(Supplement 3):739. [DOI: 10.1002/ijgo.12583] - DOI
    1. Sayyah-Melli M, Pourazad S, Gharebaghi PM, Ouladsahebmadarek E, Jafari-Shobeiri M, Rahmani V. The comparative effect of combination of metformin and megestrol acetate with megestrol acetate alone on endometrial growth disorders. International Journal of Women's Health and Reproduction Sciences 2018;6(2):211-5. [DOI: 10.15296/ijwhr.2018.35] - DOI
Shan 2014 {published data only}
    1. Shan W, Wang C, Zhang Z, Gu C, Ning C, Luo X, et al. Conservative therapy using metformin plus megestrol acetate for endometrial atypical hyperplasia: preliminary results of a pilot study. International Journal of Gynecological Cancer 2014;24(9 Suppl 4):1306-7. [DOI: 10.1097/01.IGC.0000457075.08973.89] - DOI
    1. Shan W, Wang C, Zhang Z, Gu C, Ning C, Luo X, et al. Conservative therapy with metformin plus megestrol acetate for endometrial atypical hyperplasia. Journal of Gynecologic Oncology 2014;25(3):214-20. [DOI: 10.3802/jgo.2014.25.3.214] - DOI - PMC - PubMed
Sharifzadeh 2016 {published data only}
    1. Sharifzadeh F, Aminimoghaddam S, Kashanian M, Fazaeli M, Sheikhansari N. A comparison between the effects of metformin and megestrol on simple endometrial hyperplasia. Gynecological Endocrinology 2016;33(2):1-4. - PubMed
    1. Sharifzadeh F, Aminimoghaddam S, Kashanian M, Fazaeli M, Sheikhansari N. A comparison between the effects of metformin and megestrol on simple endometrial hyperplasia. Gynecological Endocrinology 2017;33(2):152-5. [DOI: 10.1080/09513590.2016.1223285] - DOI - PubMed
Tabrizi 2014 {published data only}
    1. Tabrizi AD, Melli MS, Foroughi M, Ghojazadeh M, Bidadi S. Antiproliferative effect of metformin on the endometrium − a clinical trial. Asian Pacific Journal of Cancer Prevention 2014;15(23):10067-70. - PubMed
Tehranian 2021 {published data only}
    1. Tehranian A, Ghahghaei-Nezamabadi A, Arab M, Khalagi K, Aghajani R, Sadeghi S. The impact of adjunctive metformin to progesterone for the treatment of non-atypical endometrial hyperplasia in a randomized fashion, a placebo-controlled, double blind clinical trial. Journal of Gynecology Obstetrics and Human Reproduction 2021;50(6):101863. [DOI: 10.1016/j.jogoh.2020.101863] - DOI - PubMed
Yang 2020 {published data only}
    1. Yang B, Yierfulati G, Guan J, Chen X. Effect of megestrol acetate plus metformin as fertility-sparing treatment for patients with atypical endometrial hyperplasia and well-differentiated endometrial cancer. A randomized controlled trial. International Journal of Gynecological Cancer 2019;29(Suppl 3):A4-5. [DOI: 10.1136/ijgc-2019-IGCS.7] - DOI
    1. Yang BY, Gulinazi Y, Du Y, Ning CC, Cheng YL, Shan WW, et al. Metformin plus megestrol acetate compared with megestrol acetate alone as fertility-sparing treatment in patients with atypical endometrial hyperplasia and well-differentiated endometrial cancer: a randomised controlled trial. BJOG: An International Journal of Obstetrics & Gynaecology 2020;127(7):848-57. [DOI: 10.1111/1471-0528.16108] - DOI - PubMed

References to studies excluded from this review

Acosta Torres 2019 {published data only}
    1. Acosta-Torres S, Doglioli M, Varghese A, Tanner EJ, Stone RL, Levinson KL, et al. Efficacy of combined metformin and progestin therapy for complex atypical hyperplasia and well-differentiated endometrial cancer in patients desiring fertility. Gynecologic Oncology 2019;154(Suppl 1):267. [DOI: 10.1016/j.ygyno.2019.04.620] - DOI
Campagnoli 2013 {published data only}
    1. Campagnoli C, Abbà C, Ambroggio S, Brucato T, Pasanisi P. Life-style and metformin for the prevention of endometrial pathology in postmenopausal women. Gynecological Endocrinology 2013;29(2):119-24. - PubMed
Insin 2017 {published data only}
    1. Insin P, Prueksaritanond N. Therapeutic use of metformin in diabetes and survival outcomes in endometrial cancer patients with diabetes. Asian Pacific Journal of Cancer Prevention 2018;19(5):1295–1302. [DOI: 10.22034/APJCP.2018.19.5.1295] - DOI - PMC - PubMed
Janda 2021 {published data only}
    1. Janda M, Robledo KP, Gebski V, Armes JE, Alizart M, Cummings M, et al. Complete pathological response following levonorgestrel intrauterine device in clinically stage 1 endometrial adenocarcinoma: Results of a randomized clinical trial. Gynecologic Oncology 2021;161(1):143-51. - PubMed
Kim 2014 {published data only}
    1. Kim MK, Seong SJ. Conservative treatment for atypical endometrial hyperplasia: what is the most effective therapeutic method? Journal of Gynecologic Oncology 2014;25(3):164-5. - PMC - PubMed
Kitson 2018 {published data only}
    1. Kitson S, Maskell Z, Sivalingam V, Slade R, Ali S, Burns S, et al. Pre-surgical metformin in uterine malignancy: results of the PREMIUM randomised controlled trial. BJOG: An International Journal of Obstetrics and Gynaecology 2018;125(8):e29. [DOI: 10.1111/1471-0528.15256] - DOI
    1. Kitson SJ, Maskell Z, Sivalingam VN, Allen JL, Ali S, Burns S, et al. Pre-surgical metformin in uterine malignancy (premium): a multi-center, randomized double-blind, placebo-controlled phase III trial. Clinical Cancer Research 2019;25(8):2424-32. [DOI: 10.1158/1078-0432.CCR-18-3339] - DOI - PMC - PubMed
Legro 2007 {published data only}
    1. Legro RS, Zaino RJ, Demers LM, Kunselman AR, Gnatuk CL, Williams NI, et al. The effects of metformin and rosiglitazone, alone and in combination, on the ovary and endometrium in polycystic ovary syndrome. American Journal of Obstetrics and Gynecology 2007;196(4):402.e1-402.e11. [DOI: 10.1016/j.ajog.2006.12.025] - DOI - PubMed
Lin 2016 {published data only}
    1. Lin J, Su C. Combination of Diane-35 with metformin to reverse of endometrial atypical hyperplasia and early endometrial carcinoma with polycystic ovarian syndrome. BJOG: An International Journal of Obstetrics and Gynaecology 2016;123(Suppl 2):188. [DOI: 10.1111/1471-0528.14109] - DOI
    1. Lin J. Combination of Diane-35 with metformin to reverse of endometrial atypical hyperplasia and early endometrial carcinoma with polycystic ovarian syndrome. Gynecological Endocrinology 2016;32(Suppl 1):109. [DOI: 10.3109/09513590.2016.1150635] - DOI
Mitsuhashi 2014 {published data only}
    1. Mitsuhashi A, Usui H, Satoh Y, Kiyokawa T, Shozu M. A phase II study of medroxyprogesterone acetate plus metformin as fertility-sparing treatment for atypical endometrial hyperplasia and endometrial cancer. Journal of Clinical Oncology 2014;32(15 Suppl 1):32. - PubMed
Mitsuhashi 2014a {published data only}
    1. Mitsuhashi A, Kiyokawa T, Sato Y, Shozu M. Effects of metformin on endometrial cancer cell growth in vivo: a preoperative prospective trial. Cancer 2014;120(19):2986-95. [DOI: 10.1002/cncr.28853] - DOI - PubMed
Mitsuhashi 2016 {published data only}
    1. Mitsuhashi A, Sato Y, Kiyokawa T, Koshizaka M, Hanaoka H, Shozu M. Phase II study of medroxyprogesterone acetate plus metformin as a fertility-sparing treatment for atypical endometrial hyperplasia and endometrial cancer. Annals of Oncology 2016;27(2):262-6. - PubMed
Mitsuhashi 2020 {published data only}
    1. Mitsuhashi A, Kawasaki Y, Hori M, Fujiwara T, Hanaoka H, Shozu M. Medroxyprogesterone acetate plus metformin for fertility-sparing treatment of atypical endometrial hyperplasia and endometrial carcinoma: trial protocol for a prospective, randomised, open, blinded-endpoint design, dose-response trial (FELICIA trial). BMJ Open 2020;10(2):e035416. [DOI: 10.1136/bmjopen-2019-035416] - DOI - PMC - PubMed
O'Hara 2022 {published data only}
    1. O'Hara M, Janda M, McCarthy AL, Nicklin J, Walker G, Obermair A. Patient experiences of conservative treatment for early stage endometrial cancer and endometrial hyperplasia with atypia using levonorgestrel intrauterine device: a qualitative study. Gynecologic Oncology Reports 2022;39:100914. [DOI: 10.1016/j.gore.2021.100914] - DOI - PMC - PubMed
Pérez‐López 2014 {published data only}
    1. Pérez-López FR. Metformin treatment and evolution of endometrial cancer. Climacteric 2014;17(2):207-9. - PubMed
Pino 2022 {published data only}
    1. Pino I, Iacobone AD, Vidal Urbinati AM, Di Giminiani M, Radice D, Guerrieri ME, et al. Fertility-sparing treatment for endometrial cancer: oncological and obstetric outcomes in combined therapies with levonorgestrel intrauterine device. Cancers 2022;14(9):2170. [DOI: 10.3390/cancers14092170] - DOI - PMC - PubMed
Randall 2014 {published data only}
    1. Randall LM, Gibson SJ, Monk BJ. The American Society of Clinical Oncology 50th Annual Meeting 2014: an overview and summary of selected abstracts. Gynecologic Oncology 2014;134(2):222-7. [DOI: 10.1016/j.ygyno.2014.07.086] - DOI - PubMed
Seebacher 2016 {published data only}
    1. Seebacher V, Bergmeister B, Grimm C, Koelbl H, Reinthaller A, Polterauer S. The prognostic role of metformin in patients with endometrial cancer: a retrospective study. European Journal of Obstetrics & Gynecology & Reproductive Biology 2016;203:291-6. [DOI: 10.1016/j.ejogrb.2016.06.013] - DOI - PubMed
Shen 2008 {published data only}
    1. Shen ZQ, Zhu HT, Lin JF. Reverse of progestin-resistant atypical endometrial hyperplasia by metformin and oral contraceptives. Obstetrics & Gynecology 2008;112(2):465-7. - PubMed
Sivalingam 2015 {published data only}
    1. Sivalingam VN, McVey R, Kitson S, Gilmour K, Ali S, Roberts C, et al. Pre-surgical window study of metformin in obesity-driven endometrial cancer. Gynecologic Oncology 2015;137:18. [DOI: 10.1016/j.ygyno.2015.01.042] - DOI
Sivalingam 2016 {published data only}
    1. Sivalingam VN, Kitson S, McVey R, Roberts C, Pemberton P, Gilmour K, et al. Measuring the biological effect of presurgical metformin treatment in endometrial cancer. British Journal of Cancer 2016;114(3):281-9. [DOI: 10.1038/bjc.2015.453] - DOI - PMC - PubMed
Yates 2017 {published data only}
    1. Yates MS, Basen-Engquist K, Zhang Q, Schmandt R, Medepalli M, Nebgen DR, et al. Prospective randomized biomarker study of metformin and lifestyle intervention for prevention in obese postmenopausal women at increased risk for endometrial cancer. Journal of Clinical Oncology 2017;35(15 Suppl 1):1551.
    1. Yates MS, Coletta AM, Zhang Q, Schmandt RE, Medepalli M, Nebgen D, et al. Prospective randomized biomarker study of metformin and lifestyle intervention for prevention in obese women at increased risk for endometrial cancer. Cancer Prevention Research (Philadelphia, Pa.) 2018;11(8):477-90. [DOI: 10.1158/1940-6207.CAPR-17-0398] - DOI - PMC - PubMed
You 2016 {published data only}
    1. You B, Dugue A, Leary A, Rodrigues M, Follana P, Maucort-Boulch D, et al. ENDOLA: a GINECO-GINEGEPS French NCI sponsored phase I/II trial to assess the safety and efficacy of metronomic cyclophosphamide, metformin and OLAparib in recurrent advanced/metastatic endometrial cancer patients. Annals of Oncology 2016;27:vi311. [DOI: 10.1093/annonc/mdw374.49] - DOI
Zhou 2015 {published data only}
    1. Zhou R, Yang Y, Lu Q, Wang J, Miao Y, Wang S, et al. Prognostic factors of oncological and reproductive outcomes in fertility-sparing treatment of complex atypical hyperplasia and low-grade endometrial cancer using oral progestin in Chinese patients. Gynecological Oncology 2015;139(3):424-8. - PubMed

References to ongoing studies

NCT01686126 {published data only}
    1. NCT01686126. Improving the treatment for women with early stage cancer of the uterus (feMMe) [A phase II randomised clinical trial of Mirena® ± metformin ± weight loss intervention in patients with early stage cancer of the endometrium]. clinicaltrials.gov/study/NCT01686126 (first received 12 September 2012).
NCT02035787 {published data only}
    1. NCT02035787. Metformin with the levonorgestrel-releasing intrauterine device for the treatment of complex atypical hyperplasia (CAH) and endometrial cancer (EC) in non-surgical patients. clinicaltrials.gov/study/NCT02035787 (first received 10 January 2014).
NCT04576104 {published data only}
    1. NCT04576104. Megestrol acetate compared with megestrol acetate and metformin to prevent endometrial cancer [Surgical window of opportunity study of megestrol acetate compared with megestrol acetate and metformin for endometrial intraepithelial neoplasia]. clinicaltrials.gov/study/NCT04576104 (first received 3 October 2020).
NCT05292573 {published data only}
    1. NCT05292573. Longitudinal follow-up in women with endometrial hyperplasia without atypia [MicroRNAs as biomarkers of predicting future endometrial malignancy and longitudinal follow-up with randomized intervention in women with endometrial hyperplasia without atypia]. clinicaltrials.gov/study/NCT05292573 (first received 4 August 2021).
NCT05316935 {published data only}
    1. NCT05316935. GnRHa + letrozole in progestin-insensitive endometrial cancer and atypical hyperplasia patients [Gonadotropin-releasing hormone agonist (GnRHa) plus letrozole in progestin-insensitive early-stage endometrial cancer and atypical hyperplasia patients with conservative treatment]. www.clinicaltrials.gov/study/NCT05316935 (first received 29 March 2022).
PACTR201908498370196 {published data only}
    1. PACTR201908498370196. Metformin versus levonorgestrel-releasing intrauterine device (Mirena) in the management of endometrial hyperplasia. pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=9335 (first received 22 August 2019).

Additional references

Aljofan 2019
    1. Aljofan M, Riethmacher D. Anticancer activity of metformin: a systematic review of the literature. Future Science OA 2019;5(8):FSO410. - PMC - PubMed
BNF 2022
    1. Joint Formulary Committee. British National Formulary. 83rd edition. London: BMJ Group and Pharmaceutical Press, 2022.
Cetinkalp 2009
    1. Cetinkalp S, Karadeniz M, Erdogan M, Zengi A, Cetintas V, Tetik A, et al. Apolipoprotein E gene polymorphism and polycystic ovary syndrome patients in Western Anatolia, Turkey. Journal of Assisted Reproduction and Genetics January 2009;26:1-6. - PMC - PubMed
Chae‐Kim 2021
    1. Chae-Kim J, Garg G, Gavrilova-Jordan L, Blake LE, Wu Q, Hayslip CC. Outcomes of women treated with progestin and metformin for atypical endometrial hyperplasia and early endometrial cancer: a systematic review and meta-analysis. International Journal of Gynecologic Cancer 2021;31(12):1499-505. [DOI: 10.1136/ijgc-2021-002699] - DOI - PubMed
Cohen 1988
    1. Cohen J. Statistical Power Analysis for the Behavioural Sciences. 2nd edition. Hillsdale, NJ: Lawrence Eribaum, 1988.
Covidence [Computer program]
    1. Covidence. Version 7.1.2. Melbourne: Veritas Health Innovation. Available at www.covidence.org.
De Jager 2010
    1. Jager J, Kooy A, Lehert P, Wulffele MG, Kolk J, Bets D, et al. Long term treatment with metformin in patients with type 2 diabetes and risk of vitamin B-12 deficiency: randomised placebo controlled trial. BMJ (Clinical Research ed) 2010;340:c2181. [PMID: ] - PMC - PubMed
Deswal 2020
    1. Deswal R, Narwal V, Dang A, Pundir CS. The prevalence of polycystic ovary syndrome: a brief systematic review. Journal of Human Reproductive Sciences 2020;13(4):261. - PMC - PubMed
Doherty 2020
    1. Doherty MT, Sanni OB, Coleman HG, Cardwell CR, McCluggage WG, Quinn D, et al. Concurrent and future risk of endometrial cancer in women with endometrial hyperplasia: A systematic review and meta-analysis. PLoS One 2020;15(4):e0232231. - PMC - PubMed
Dowling 2011
    1. Dowling RJ, Goodwin PJ, Stambolic V. Understanding the benefit of metformin use in cancer treatment. BMC Medicine 2011;9:33. [PMID: ] - PMC - PubMed
Erdemoglu 2009
    1. Erdemoglu E, Güney M, Giray SG, Take G, Mungan T. Effects of metformin on mammalian target of rapamycin in a mouse model of endometrial hyperplasia. European Journal of Obstetrics & Gynecology and Reproductive Biology 2009;145(2):195-9. - PubMed
ESHRE/ASRM 2004
    1. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertility and Sterility 2004;81(1):19-25. [PMID: ] - PubMed
Fraison 2020
    1. Fraison E, Kostova E, Moran LJ, Bilal S, Ee CC, Venetis C, et al. Metformin versus the combined oral contraceptive pill for hirsutism, acne, and menstrual pattern in polycystic ovary syndrome. Cochrane Database of Systematic Reviews 2020, Issue 1. Art. No: CD005552. [DOI: 10.1002/14651858.CD005552.pub3] - DOI - PMC - PubMed
Gallos 2013
    1. Gallos ID, Krishan P, Shehmar M, Ganesan R, Gupta JK. Relapse of endometrial hyperplasia after conservative treatment: a cohort study with long-term follow-up. Human Reproduction (Oxford, England) 2013;28(5):1231-6. [PMID: ] - PubMed
GRADEpro GDT [Computer program]
    1. GRADEpro GDT. Hamilton (ON): McMaster University (developed by Evidence Prime), Accessed 19 April 2023. Available at gradepro.org.
Higgins 2017
    1. Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.2.0 (updated June 2017). The Cochrane Collaboration, 2017. Available from training.cochrane.org/handbook/archive/v5.2/.
Higgins 2022
    1. Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022. Available from training.cochrane.org/handbook/archive/v6.3.
Holm 2012
    1. Holm NS, Glintborg D, Andersen MS, Schledermann D, Ravn P. The prevalence of endometrial hyperplasia and endometrial cancer in women with polycystic ovary syndrome or hyperandrogenism. Acta Obstetricia et Gynecologica Scandinavica 2012;91(10):1173-6. [PMID: ] - PubMed
IRCT201410275283N11
    1. Comparison of metformin‐megestrol acetate combination and megestrol acetate alone on endometrial histology in patients with disordered proliferative or hyperplastic endometrium. www.irct.ir/searchen.php?keyword=IRCT201410275283N11&field=a&lang=en 2018.
Johnson 2023
    1. Johnson JE, Daley D, Tarta C, Stanciu PI. Risk of endometrial cancer in patients with polycystic ovarian syndrome: a meta‑analysis. Oncology Letters 2023;25(4):1-9. - PMC - PubMed
Kurman 1985
    1. Kurman RJ, Kaminski PF, Norris HJ. The behavior of endometrial hyperplasia. A long-term study of "untreated" hyperplasia in 170 patients. Cancer 1985;56(2):403-12. [PMID: ] - PubMed
Lacey 2010
    1. Lacey JV Jr, Sherman ME, Rush BB, Ronnett BM, Ioffe OB, Duggan MA, et al. Absolute risk of endometrial carcinoma during 20-year follow-up among women with endometrial hyperplasia. Journal of Clinical Oncology 2010;28:788-92. [DOI: 10.1200/JCO.2009.24.1315] [PMID: ] - DOI - PMC - PubMed
Meyer 2007
    1. Meyer C, McGrath BP, Teede HJ. Effects of medical therapy on insulin resistance and the cardiovascular system in polycystic ovary syndrome. Diabetes Care 2007;30(3):471-8. - PubMed
Moher 2009
    1. Moher D, Liberati A, Tetzlaff J, Altman D G. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 2009;339:b2535. [DOI: 10.1136/bmj.b2535] - DOI - PMC - PubMed
Morley 2017
    1. Morley LC, Tang T, Yasmin E, Norman RJ, Balen AH. Insulin‐sensitising drugs (metformin, rosiglitazone, pioglitazone, D‐chiro‐inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. Cochrane Database of Systematic Reviews 2017, Issue 11. Art. No: CD003053. [DOI: 10.1002/14651858.CD003053.pub6] - DOI - PMC - PubMed
NCT01968317
    1. Megestrol acetate plus metformin to megestrol acetate in patients with endometrial atypical hyperplasia or early stage endometrial adenocarcinoma. clinicaltrials.gov/study/NCT01968317 (first received 16 October 2013).
Nees 2022
    1. Nees LK, Heublein S, Steinmacher S, Juhasz‐Böss I, Brucker S, Tempfer CB, et al. Endometrial hyperplasia as a risk factor of endometrial cancer. Archives of Gynecology and Obstetrics January 2022;306:407-21. - PMC - PubMed
Nevadunsky 2014
    1. Nevadunsky NS, Van Arsdale A, Strickler HD, Moadel A, Kaur G, Frimer M, et al. Metformin use and endometrial cancer survival. Gynecologic Oncology 2014;132(1):236-40. [PMID: ] - PMC - PubMed
Raglan 2019
    1. Raglan O, Kalliala I, Markozannes G, Cividini S, Gunter MJ, Nautiyal J, et al. Risk factors for endometrial cancer: an umbrella review of the literature. International Journal of Cancer 2019;145(7):1719-30. - PubMed
RCOG/BSGE 2016
    1. Royal College of Obstetrics & Gynaecology and British Society for Gynaecological Endoscopy (RCOG/BSGE). Management of endometrial hyperplasia. Green-top guideline no. 67. RCOG/BSGE joint guideline [No GT. Management of Endometrial Hyperplasia]. RCOG BSGE Joint Guideline 2016;67(30):125-9.
RevMan Web 2023 [Computer program]
    1. Review Manager Web. Version 7.1.2. Copenhagen: Cochrane, 2023. Available at revman.cochrane.org.
Ring 2022
    1. Ring KL, Mills AM, Modesitt SC. Endometrial hyperplasia. American Journal of Obstetrics & Gynaecology 2022;140(6):1061-75. - PubMed
Rosato 2011
    1. Rosato V, Zucchetto A, Bosetti C, Dal Maso L, Montella M, Pelucchi C, et al. Metabolic syndrome and endometrial cancer risk. Annals of Oncology 2011;22(4):884-9. [PMID: ] - PubMed
Session 2003
    1. Session DR, Kalli KR, Tummon IS, Damario MA, Dumesic DA. Treatment of atypical endometrial hyperplasia with an insulin-sensitizing agent. Gynecological Endocrinology 2003;17(5):405-7. [DOI: 10.1080/09513590312331290298] - DOI - PubMed
Torres 2012
    1. Torres ML, Weaver AL, Kumar S, Uccella S, Famuyide AO, Cliby WA, et al. Risk factors for developing endometrial cancer after benign endometrial sampling. Obstetrics and Gynecology 2012;120(5):998-1004. [PMID: ] - PMC - PubMed
Vrachnis 2016
    1. Vrachnis N, Lavazzo C, Iliodromiti Z, Sifakis S, Alexandrou A, Siristatidis C, et al. Diabetes mellitus and gynecologic cancer: molecular mechanisms, epidemiological, clinical and prognostic perspectives. Archives of Gynaecology and Obstetrics 2016;293(2):239-46. - PubMed
Watter 2021
    1. Wattar BH, Fisher M, Bevington L, Talaulikar V, Davies M, Conway G, et al. Clinical practice guidelines on the diagnosis and management of polycystic ovary syndrome: a systematic review and quality assessment study. Journal of Clinical Endocrinolology & Metabolism August 2021;106(8):2436-2446. - PMC - PubMed
Wu 2009
    1. Wu J, Zhu Y, Jiang Y, Cao Y. Effects of metformin and ethinyl estradiol-cyproterone acetate on clinical, endocrine and metabolic factors in women with polycystic ovary syndrome. Gynecological Endocrinology 2008 Jan;24(7):392-8. - PubMed
Yang 2011
    1. Yang S, Thiel KW, Leslie KK. Progesterone: the ultimate endometrial tumor suppressor. Trends in Endocrinology and Metabolism 2011;22(4):145-52. [PMID: ] - PMC - PubMed

References to other published versions of this review

Clement 2016
    1. Clement NS, Oliver TRW, Shiwani H, Sanner JRF, Mulvaney CA, Atiomo W. Metformin for endometrial hyperplasia. Cochrane Database of Systematic Reviews 2016, Issue 5. Art. No: CD012214. [DOI: 10.1002/14651858.CD012214.pub2] - DOI - PMC - PubMed
Clement 2017
    1. Clement NS, Oliver TRW, Shiwani H, Sanner JRF, Mulvaney CA, Atiomo W. Metformin for endometrial hyperplasia. Cochrane Database of Systematic Reviews 2017, Issue 10. Art. No: CD012214. [DOI: 10.1002/14651858.CD012214.pub2] - DOI - PMC - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources